# Intradermal Rabies Immunization Using NanoJect: A Comparative Study

> **NCT02538185** · PHASE1 · COMPLETED · sponsor: **University of Lausanne Hospitals** · enrollment: 66 (actual)

## Conditions studied

- Intradermal (ID) Vaccination Device

## Interventions

- **DEVICE:** NanoJect device (DebioJect™)
- **DEVICE:** Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus)
- **DEVICE:** Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)
- **DRUG:** Vaccin rabique Pasteur®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02538185
- **Lead sponsor:** University of Lausanne Hospitals
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2020-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02538185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02538185, "Intradermal Rabies Immunization Using NanoJect: A Comparative Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02538185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*